Presidio, Boehringer join forces for hep C drug combo trial

03/14/2013 | American City Business Journals

Presidio Pharmaceuticals and Boehringer Ingelheim agreed to collaborate in a midstage clinical study of an interferon-free, combination therapy for hepatitis C. The trial, which will start next quarter, will evaluate Presidio's PPI-668, in combination with Boehringer's protease inhibitors BI201335 and BI207127.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC